Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Association between ERCC1 C8092A and ERCC2 K751Q polymorphisms and risk of adult glioma: a meta-analysis

Authors: Zhiqin Xu, Wenbin Ma, Lu Gao, Bing Xing

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

While the ERCC1 C8092A and ERCC2 K751Q polymorphisms have received much attention for their potential associations with adult glioma risk, inferences from such studies are hindered by their limited statistical power and conflicting results. The aim of this meta-analysis is to provide a relatively comprehensive account of the association between these two polymorphisms and adult glioma risk. A literature search for eligible studies published before September 1, 2013 was conducted in PubMed, Embase, Web of Science, Cochrane Library, and CNKI databases. Pooled odds ratios (ORs) with their corresponding 95 % confidence intervals (95 % CIs) were used to evaluate the strength of the association under a fixed or random effect model according to heterogeneity test results. All analyses were performed using STATA software, version 12.0. Ten case–control studies were included in this meta-analysis, with a total of 5,843 adult glioma patients and 8,139 healthy controls. For ERCC1 C8092A (dbSNP: rs3212986, C>A), the combined results show that carriers of the AA genotype may be associated with a higher risk of adult glioma than carriers of the CA and CC genotypes. Stratified analyses show that the magnitude of the effect was especially significant among Asians, indicating ethnicity differences in adult glioma susceptibility. For ERCC2 K751Q (dbSNP: rs13181, A>C), the pooled ORs were not significant in the overall population, although all of the ORs were greater than 1. However, Asians seem to be significantly more susceptible to adult glioma than Caucasians. The results of this meta-analysis indicate that the AA genotype of ERCC1 C8092A may be associated with a higher risk of adult glioma than the CA and CC genotypes and that the risk allele of ERCC2 K751Q confers a significant susceptibility to adult glioma, especially in Asian populations. These polymorphisms may be used along with other genetic markers to identify individuals at high risk for adult glioma.
Literature
1.
Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2:494–503. quiz 1 p following 16.PubMedCrossRef
2.
Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the united states in 2005–2009. Neuro Oncol. 2012;14 Suppl 5:v1–v49.PubMedCentralPubMedCrossRef
3.
Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol. 2004;36:1046–69.PubMedCrossRef
4.
Plascak JJ, Fisher JL. Area-based socioeconomic position and adult glioma: a hierarchical analysis of surveillance epidemiology and end results data. PLoS One. 2013;8:e60910.PubMedCentralPubMedCrossRef
5.
6.
Burcham PC. Internal hazards: baseline DNA damage by endogenous products of normal metabolism. Mutat Res. 1999;443:11–36.PubMedCrossRef
7.
Liu BH, Yu FY, Wu TS, Li SY, Su MC, et al. Evaluation of genotoxic risk and oxidative DNA damage in mammalian cells exposed to mycotoxins, patulin and citrinin. Toxicol Appl Pharmacol. 2003;191:255–63.PubMedCrossRef
8.
9.
Ames BN. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat Res. 2001;475:7–20.PubMedCrossRef
10.
Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:193–204.PubMedCrossRef
11.
Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.PubMed
12.
13.
Smith JS, Tachibana I, Pohl U, Lee HK, Thanarajasingam U, et al. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics. 2000;64:44–50.PubMedCrossRef
14.
Garcia-Closas M, Malats N, Real FX, Welch R, Kogevinas M, et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:536–42.PubMedCrossRef
15.
16.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.PubMedCentralPubMedCrossRef
17.
Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, et al. Strengthening the Reporting of Genetic Association studies (STREGA): an extension of the STROBE statement. Hum Genet. 2009;125:131–51.PubMedCrossRef
18.
Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.PubMedCrossRef
19.
20.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef
21.
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–80.PubMedCrossRef
22.
23.
Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, et al. Association of an ercc1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev. 2000;9:843–7.PubMed
24.
25.
Liu Y, Scheurer ME, El-Zein R, Cao Y, Do KA, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009;18:204–14.PubMedCentralPubMedCrossRef
26.
McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, Ruder AM, Butler M, et al. Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev. 2009;18:1118–26.PubMedCentralPubMedCrossRef
27.
Chen DQ, Yao DX, Zhao HY, Yang SJ. DNA repair gene ERCC1 and XPD polymorphisms predict glioma susceptibility and prognosis. Asian Pac J Cancer Prev. 2012;13:2791–4.PubMedCrossRef
28.
Zhang N, Lin LY, Zhu LL, Wu F, Wen H, et al. ERCC1 polymorphisms and risk of adult glioma in a Chinese population: a hospital-based case–control study. Cancer Invest. 2012;30:199–202.PubMedCrossRef
29.
30.
Caggana M, Kilgallen J, Conroy JM, Wiencke JK, Kelsey KT, et al. Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev. 2001;10:355–60.PubMed
31.
Rajaraman P, Hutchinson A, Wichner S, Black PM, Fine HA, et al. DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol. 2010;12:37–48.PubMedCentralPubMedCrossRef
32.
Luo KQ, Mu SQ, Wu ZX, Shi YN, Peng JC. Polymorphisms in DNA repair genes and risk of glioma and meningioma. Asian Pac J Cancer Prev. 2013;14:449–52.PubMedCrossRef
33.
Vanan I, Dong Z, Tosti E, Warshaw G, Symons M, et al. Role of a DNA damage checkpoint pathway in ionizing radiation-induced glioblastoma cell migration and invasion. Cell Mol Neurobiol. 2012;32:1199–208.PubMedCrossRef
34.
Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J. 2009;417:639–50.PubMedCentralPubMedCrossRef
35.
36.
Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41:899–904.PubMedCrossRef
37.
Rajaraman P, Melin BS, Wang Z, McKean-Cowdin R, Michaud DS, et al. Genome-wide association study of glioma and meta-analysis. Hum Genet. 2012;131:1877–88.PubMedCentralPubMedCrossRef
38.
Lai R, Crevier L, Thabane L. Genetic polymorphisms of glutathione S-transferases and the risk of adult brain tumors: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2005;14:1784–90.PubMedCrossRef
39.
Tan D, Xu J, Li Y, Lai R. Association between +61g polymorphism of the EGF gene and glioma risk in different ethnicities: a meta-analysis. Tohoku J Exp Med. 2010;222:229–35.PubMedCrossRef
40.
Jacobs DI, Bracken MB. Association between XRCC1 polymorphism 399 g→a and glioma among Caucasians: a systematic review and meta-analysis. BMC Med Genet. 2012;13:97.PubMedCentralPubMedCrossRef
41.
He F, Xia Y, Liu H, Li J, Wang C. P53 codon 72 arg/pro polymorphism and glioma risk: an updated meta-analysis. Tumour Biol. 2013;34:3121–30.PubMedCrossRef
42.
Lu Q, Dai D, Zhao W, Wang L, Yue Z, et al. Association between mthfr 677c>t polymorphism and risk of gliomas: evidence from a meta-analysis. Tumour Biol. 2013;34:2801–7.PubMedCrossRef
Metadata
Title
Association between ERCC1 C8092A and ERCC2 K751Q polymorphisms and risk of adult glioma: a meta-analysis
Authors
Zhiqin Xu
Wenbin Ma
Lu Gao
Bing Xing
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1420-9

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

The MMP-1, MMP-2, and MMP-9 gene polymorphisms and susceptibility to bladder cancer: a meta-analysis

Research Article

Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India

Research Article

Truncation of inhibitor of growth family protein 5 effectively induces senescence, but not apoptosis in human tongue squamous cell carcinoma cell line

Research Article

Serum levels of osteopontin as a prognostic factor in patients with oral squamous cell carcinoma

Research Article

EMP1 inhibits nasopharyngeal cancer cell growth and metastasis through induction apoptosis and angiogenesis

Research Article

The variant interleukin 1f7 rs3811047 G>A was associated with a decreased risk of gastric cardiac adenocarcinoma in a Chinese Han population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits